+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Targeted Oncology Therapeutics: Lung Cancers

  • ID: 5457687
  • Report
  • October 2021
  • Region: Global
  • 82 Pages
  • Greystone Associates

FEATURED COMPANIES

  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Genzyme
  • Janssen Biotech
  • Lonza Biologics
A number of factors are changing the way market participants view the cancer therapeutics market. These factors are evident in the disease targets and drug classes that comprise a significant number of recent trials. After decades of disappointment and missed financial objectives, the genetic underpinnings of disease are converging with improved computer-assisted pharmacological decision making. Market sector participants now find themselves pursuing realistic therapeutic strategies that have the potential to fulfil product strategies in both scientific and human terms.

As immuno-therapeutics in general - and immuno-oncology in particular - move to the forefront, the major oncology drug developers are beginning to align with specific therapeutic approaches, such as PARP and PD-1/PD-L1. Our analytics analysis of current active oncology trial data reveals these factors and how they are affecting the oncology drug development landscape.

What You Will Learn

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?
  • Drug treatment resources
  • Competitive therapy map
  • Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Genzyme
  • Janssen Biotech
  • Lonza Biologics
  • Executive Summary
  • The Recombinant Drug Ecosystem
  • Biological Drug Activity by Region
  • Biological Oncology Market Leaders
  • Oncology mAbs: Competitive Considerations
  • mAbs and Targeted Oncology Therapeutics
  • Historical Growth of Biologicals
  • Leading Biological Drug Companies - Activity by Drug & Segment
  • FDA Approved mAbs Indicated for Lung Cancers
  • FDA Approved TKIs Indicated for Lung Cancers
  • Key Therapeutic Targets
  • EGFR
  • VEGF
  • ALK Gene
  • PD-L1
  • ROS-1 Gene
  • RET
  • The Addressable Market
  • Drugs in Development
  • Leading Lung Cancer Supplier Assessments
Note: Product cover images may vary from those shown
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celltrion
  • Daiichi Sankyo
  • Eli Lilly
  • Genentech
  • Genzyme
  • GlaxoSmithKline
  • Janssen Biotech
  • Kyowa Kirin
  • Merck Sharp & Dohme
  • Pfizer
  • Regeneron Pharmaceuticals
  • United Therapeutics
  • Roche
  • EMD Serono
  • Immunex
  • Lonza Biologics
  • Lonza AG
  • Seattle Genetics
  • Biogen
Note: Product cover images may vary from those shown